Hydroxysteroid 17-beta dehydrogenase 14 (HSD17B14) has been identified as a predictive biomarker for successful breast cancer treatment with tamoxifen [44] but its expression varies among the six tissues in the dataset. This evidence concerns the gene HSD17B14 and breast carcinoma.